Literature DB >> 2842558

Prostaglandins, leukotrienes, and other arachidonic acid metabolites in the pathogenesis of otitis media.

T T Jung1.   

Abstract

Among the various inflammatory mediators of otitis media (OM), metabolites of arachidonic acid (AA) such as prostaglandins (PGs) and leukotrienes (LTs) appear to play an important role in the pathogenesis of otitis media. In an effort to investigate the role of AA metabolites on the pathogenesis of otitis media, concentrations of AA metabolites were measured in middle ear effusion (MEE) from human and paralleling animal models of otitis media and the effects of inhibitors of AA metabolism, antibiotics, and tympanostomy tube (TT) on the outcome of animal models of OM were studied. Concentrations of AA metabolites in MEE were higher in the younger age group. Levels of PGE2 and LTB4 in MEE seem to represent the degree of inflammation of OM best. Lipoxygenase products seem to be associated with the mucoid type of MEE. In the study of animal models of OM, combined models and ears with TT showed more inflammation than single models and ears without TT. Study of the therapeutic use of inhibitors of AA metabolism, penicillin, and TT showed that lipoxygenase products may be more important in the pathogenesis of OM than the cyclo-oxygenase products, and that the use of a combination of penicillin and corticosteroid produces the best results. It is clear from these studies that arachidonic acid metabolites are important inflammatory mediators in the pathogenesis of otitis media.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842558     DOI: 10.1288/00005537-198809000-00013

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  12 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Cytolytic complement activity in otitis media with effusion.

Authors:  M Närkiö-Mäkelä; S Meri
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  Ibuprofen inhibits localized bone resorption in the middle ear.

Authors:  M C Jungkeit; R A Chole
Journal:  Calcif Tissue Int       Date:  1991-04       Impact factor: 4.333

4.  Arachidonic acid metabolism by isolated and cultured middle ear epithelial cells from the chinchilla.

Authors:  T Harada; S K Juhn; Y Kim; Y Sakakura
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

5.  Effect of modulation of polymorphonuclear leukocyte migration with anti-CD18 antibody on pathogenesis of experimental otitis media in guinea pigs.

Authors:  J Patel; T Chonmaitree; F Schmalstieg
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

6.  Release of leukotriene B4 from human neutrophils after interaction with nontypeable Haemophilus influenzae.

Authors:  R Garofalo; H Faden; S Sharma; P L Ogra
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

Review 7.  Importance of respiratory viruses in acute otitis media.

Authors:  Terho Heikkinen; Tasnee Chonmaitree
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

8.  Mutation in Phex gene predisposes BALB/c-Phex(Hyp-Duk)/Y mice to otitis media.

Authors:  Fengchan Han; Heping Yu; Ping Li; Jiangping Zhang; Cong Tian; Hongbo Li; Qing Yin Zheng
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

9.  The role of inflammatory mediators in the pathogenesis of otitis media and sequelae.

Authors:  Steven K Juhn; Min-Kyo Jung; Mark D Hoffman; Brian R Drew; Diego A Preciado; Nicholas J Sausen; Timothy T K Jung; Bo Hyung Kim; Sang-Yoo Park; Jizhen Lin; Frank G Ondrey; David R Mains; Tina Huang
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-09-30       Impact factor: 3.372

Review 10.  The immunoregulatory and allergy-associated cytokines in the aetiology of the otitis media with effusion.

Authors:  Marina G Smirnova; John P Birchall; Jeffrey P Pearson
Journal:  Mediators Inflamm       Date:  2004-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.